Humedix Co Ltd
KOSDAQ:200670
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25 550
45 250
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Humedix Co Ltd
Cash & Cash Equivalents
Humedix Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Humedix Co Ltd
KOSDAQ:200670
|
Cash & Cash Equivalents
₩80.2B
|
CAGR 3-Years
56%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Cash & Cash Equivalents
₩229.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash & Cash Equivalents
₩239.7B
|
CAGR 3-Years
59%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash & Cash Equivalents
₩48.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-6%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash & Cash Equivalents
₩134B
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
14%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Cash & Cash Equivalents
₩28.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
66%
|
CAGR 10-Years
28%
|
|
Humedix Co Ltd
Glance View
Humedix Co., Ltd. engages in the manufacture and sale of hyaluronic acid based medical devices and arthritis treatment products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2014-12-26. The firm distributes its products within domestic market and to overseas markets
See Also
What is Humedix Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
80.2B
KRW
Based on the financial report for Sep 30, 2024, Humedix Co Ltd's Cash & Cash Equivalents amounts to 80.2B KRW.
What is Humedix Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
24%
Over the last year, the Cash & Cash Equivalents growth was 581%. The average annual Cash & Cash Equivalents growth rates for Humedix Co Ltd have been 56% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
